DPP4 and Hypoglycemia: In addition, DPP-4 inhibitors and SGLT-2 inhibitors can complement each other with their different action mechanisms, and the risk of hypoglycemia is relatively low, which is expected to reduce side effects and increase the therapeutic effect.